Skip to content

Disease Activity in RA and SLE Patients and Its Relation to Muscle Performance,Fatigue and Blood Parameters

Disease Activity in Rheumatoid Arthritis and Systemic Lupus Erythematosus and Its Relation to Muscle Performance,Fatigue and Blood Parameters

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03728231
Enrollment
150
Registered
2018-11-02
Start date
2018-11-15
Completion date
2020-02-02
Last updated
2018-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatic Diseases

Brief summary

Assessment of disease activity in Rheumatoid Arthritis and Systemic lupus patients related to muscle performance, fatigue and blood parameters

Detailed description

Rheumatoid arthritis (RA) is the most common inflammatory arthritis, affecting 0.5-1% of the general population world-wide. It is primarily a disease of the joints, but abnormal systemic immune responses are evident and cause a variety of extra-articular manifestations . Physical inactivity is one of the key mechanisms affecting skeletal muscle mass and body composition, leading to progressive muscle loss and abdominal fat gain . Muscle strength and endurance are determinants of muscle performance. Relatively little is known about how muscle performance relates to RA clinical variables; also muscle performance is not routinely assessed in clinical practice among patients with RA. Decreased muscle strength has negative outcomes in RA, associating with disease activity, radiological damage and disability .Rheumatoid cachexia, including loss of muscle mass and concomitant increase in fat mass with normal or increased body weight , is a common feature in patients with RA. Assessment of inflammation in RA with markers is important to detect long-term outcome. Parameters of hemogram, particularly those including immune system elements, are important in the assessment of different diseases and/or signs. Immune system elements involve the neutrophils, lymphocytes and platelets that have a role in the control of inflammation, while also undergoing changes secondary to inflammation . Systemic lupus erythematosus (SLE) is a complex autoimmune disease with chronic relapsing-remitting course and variable manifestations varying from mild mucocutaneous to severe, life-threatening illness . It has been speculated that fatigue, a symptom frequently observed in approximately 80% of SLE patients , may contribute to a reduction in physical fitness (i.e.,muscle weakness and low cardiovascular capacity) which, in turn, leads to an impairment in the performance of activities of daily living and in the overall quality of life . SLE patients experienced decreased physical function, low dynamic muscle strength capacity, and poor quality of life, suggesting that either residual fatigue or other factors (e.g., long-term medication or systemic inflammation) may have contributed to the poor health-related findings . Celikbilek et al. observed that Neutrophil /Lymphocyte Ratio (NLR) and Platelet/Lymphocyte Ratio (PLR) in peripheral blood are simple Systemic Inflammatory Response (SIR) markers which are evaluated by blood parameters and showed that NLR possesses a diagnostic value in certain pathologies characterized by systemic or local inflammatory response. Amaylia et al. found that NLR was significantly higher in SLE than normal subjects .

Interventions

OTHERComplete blood count

taking blood sample from venous blood

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

: 1. RA diagnosis according to 1987ACR criteria,or 2010 ACR/EULAR criteria 2. SLE diagnosis according to 1982 ACRor 2012 ACRcriteria 3. Patients aged \> 18 years. 4. Stable disease with no activity during last 3 months. 5. Regular medication in last 3 months.

Exclusion criteria

1. Subjects with hematologic disorders other than anaemia. 2. Concomitant infectious or inflammatory diseases such as ulcerative colitis. 3. Liver or kidney disease. 4. Coronary heart disease. 5. Other immunological diseases. 6. Pregnant ladies. 7. Patients with end stage organ failure. 8. Patients with malignancies. 9. Patients receiving any medications affect blood picture.

Design outcomes

Primary

MeasureTime frameDescription
estimation of muscle performance in Rheumatoid arthritis and Systemic lupus patients by 30_s chair stand test (repetition 4_12) .6 monthsuse of 30\_s chair stand test(repetition 4\_12) in detection of degree of muscle performance in Rheumatoid arthritis and Systemic lupus patients .

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026